Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬ £¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

Ê׿FDAÅú×¼°¬²®Î¬Í»ÆÆÐÔADCÁÆ·¨ | 1·ÖÖÓÒ©ÎÅËÙÀÀ

2025-05-16
|
»á¼ûÁ¿£º

0517.jpgÒ½ÏßÒ©ÎÅ

1. 5ÔÂ15ÈÕ£¬£¬ £¬£¬£¬°¬²®Î¬Ðû²¼£¬£¬ £¬£¬£¬ÃÀ¹úFDAÒѼÓËÙÅú×¼ÆìÏ¿¹ÌåżÁªÒ©ÎADC£©Emrelis£¨telisotuzumab vedotin£¬£¬ £¬£¬£¬teliso-V£©ÉÏÊУ¬£¬ £¬£¬£¬ÓÃÓÚÖÎÁƾßÓиßc-MetÂѰ×Ì«¹ý±í´ï£¨OE£©µÄ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔ·ÇÁÛ×´·ÇСϸ°û·Î°©£¨NSCLC£©³ÉÄ껼Õߣ¬£¬ £¬£¬£¬ÕâЩ»¼Õß´ËǰÒѽÓÊܹýϵͳÐÔÖÎÁÆ¡£¡£¡£

2. 5ÔÂ15 ÈÕ£¬£¬ £¬£¬£¬NMPA ¹ÙÍøÏÔʾ£¬£¬ £¬£¬£¬±±º£¿£¿£¿£¿£¿£¿µ³É/Ò©Ã÷ÉúÎïάÀ­ÜÕø ¦Â-CAN103 »ñÅúÉÏÊУ¬£¬ £¬£¬£¬ÓÃÓÚ 12 Ëê¼°ÒÔÉÏÇàÉÙÄêºÍ³ÉÈË I ÐÍºÍ ¢ó Ð͸êл²¡»¼Õߵĺã¾ÃÃ¸Ìæ»»ÖÎÁÆ¡£¡£¡£ÕâÒ²ÊÇÖйúÊ׸öÕë¶Ô¸êл²¡¿ª·¢µÄÃ¸Ìæ»»ÁÆ·¨£¨ERT£©¡£¡£¡£

3. 5ÔÂ16ÈÕ£¬£¬ £¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬ £¬£¬£¬¿ÆÂײ©Ì©É걨µÄ×¢ÉäÓ뿵ɳÍ×Öéµ¥¿¹ÄâÄÉÈëÓÅÏÈÉóÆÀ£¬£¬ £¬£¬£¬ÓÃÓÚ¼ÈÍù½ÓÊܹýÄÚÉøÍ¸ÖÎÁÆÇÒÔÚÍíÆÚ»ò×ªÒÆÐԽ׶νÓÊܹýÆäËûϵͳÖÎÁƵIJ»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔ¼¤ËØÊÜÌåÑôÐÔ£¨HR+£©ÇÒÈË±íÆ¤Éú³¤Òò×ÓÊÜÌå2ÒõÐÔ£¨HER2-£©ÈéÏÙ°©³ÉÈË»¼Õß¡£¡£¡£Â«¿µÉ³Í×Öéµ¥¿¹ÊÇÒ»¿îÐÂÐÍTROP2°ÐÏò¿¹ÌåżÁªÒ©ÎADC£©£¬£¬ £¬£¬£¬´ËǰÒѾ­ÔÚÖйú»ñÅúÁ½Ïî˳Ӧ֢¡£¡£¡£

4. 5ÔÂ15ÈÕ£¬£¬ £¬£¬£¬NMPA¹ÙÍøÐû²¼£¬£¬ £¬£¬£¬Åú×¼º£Ë¼¿ÆÉ걨µÄ1ÀàÁ¢ÒìÒ©°²Èð¿Ë·Ò×¢ÉäÒº£¬£¬ £¬£¬£¬¸ÃÒ©ÊÊÓÃÓÚÖÎÁƸ¹²¿ÊÖÊõºóµÄÇá¡¢ÖжÈÌÛÍ´¡£¡£¡£¹ûÈ»×ÊÁÏÏÔʾ£¬£¬ £¬£¬£¬°²Èð¿Ë·Ò£¨HSK21542£©ÊÇÒ»¿îÍâÖÜkappa°¢Æ¬ÊÜÌåÑ¡ÔñÐÔ¼¤¶¯¼Á¡£¡£¡£

ͶÈÚÒ©ÊÂ

1. ¿ËÈÕ£¬£¬ £¬£¬£¬¿Æ°ÔÉúÎïÐû²¼£¬£¬ £¬£¬£¬ÒÑÓëÈÕ±¾ÈýÁ⻯ѧ¿Ø¹É¼¯ÍÅÆìϵÄÈýÁâÌï±ßÖÆÒ©ÃÀ¹ú¹«Ë¾£¨Mitsubishi Tanabe Pharma America, Inc., ¼ò³ÆMTPA£©Ç©ÊðÏàÖúЭÒé¡£¡£¡£Ë«·½½«Î§ÈÆÒ»¸öÈ«ÇòÊ×´´µÄÃâÒßϸ°ûÀà°Ðµã£¬£¬ £¬£¬£¬¿ª·¢Ò»¿îȫлúÖÆµÄ¿¹ÌåÒ©ÎïżÁªÎADC£©£¬£¬ £¬£¬£¬¸ÃÏîÄ¿ÓÐÍû³ÉΪ¶àÖÖʵÌåÁöÊÊÓõġ°Í¨ÓÃÐÍ¡°ADCÖÎÁƼƻ®¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1. 5ÔÂ13ÈÕ£¬£¬ £¬£¬£¬Ò®Â³´óѧAkiko IwasakiͨѶÔÚ¡¶Nature immunology¡·½ÒÏþÂÛÎÄ¡°Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice¡±£¬£¬ £¬£¬£¬·¢Ã÷ÁËÔÚʹÓÃÎÞ×ô¼ÁµÄÖØ×é SARS-CoV-2 ´ÌÍ»ÂѰ׾ÙÐбÇÄÚÔöÇ¿½ÓÖֺ󣬣¬ £¬£¬£¬Çý¶¯ð¤Ä¤ IgA ·´Ó¦Éú³¤µÄÒªº¦Ï¸°ûºÍ·Ö×ÓÊÂÎñ¡£¡£¡£

[1]Kwon, Di., Mao, T., Israelow, B. et al. Mucosal unadjuvanted booster vaccines elicit local IgA responses by conversion of pre-existing immunity in mice. Nat Immunol (2025). https://doi.org/10.1038/s41590-025-02156-0

Ïà¹ØÐÂÎÅ
¡¾Nature¡¿·ÇСϸ°û·Î°©ÖÎÁÆÐ¼ƻ®£º°ÐÏò½µ½âEGFR
2020-09-03
¿ËÈÕ½ÒÏþÔÚNatureÔÓÖ¾ÉϵÄÒ»ÏîÑо¿È·¶¨ÁËTRIB3±í´ïµÄÉý¸ßÒÔ¼°EGFRµÄÎȹÌÐÔ¡¢ÔÙÑ­»·¡¢ÐźŻîÐÔÓëNSCLCÏ£ÍûµÄÔöÌíÓйØ£¬£¬ £¬£¬£¬Õ¹ÏÖÁËͨ¹ý¼ÓËÙEGFR½µ½âÀ´×ÌÈÅTRIB3-EGFRÏ໥×÷ÓÃÖÎÁÆNSCLCµÄDZÔÚ×÷Óᣡ£¡£
dzÎö£ºADCÒ©ÎïµÄ¿¹°©Ö®Â·
2019-07-24
ÃÀ¸ß÷ÔÚADCÒ©ÎïÁÙ´²Ç°Ò©Ð§Ñ§¡¢Ò©ÎﶯÁ¦Ñ§¼°Çå¾²ÐÔÆÀ¼ÛÑо¿ÁìÓòÒÑ»ýÀÛÁ˸»ºñµÄʵ¼ùÂÄÀúºÍÉîÖ¿µÄÀíÂÛ»ù´¡¡£¡£¡£ÃÀ¸ß÷ÓÐÐÒ¼ÓÈëÁ˲»ÉÙÓÚ4¸öADCÒ©ÎïµÄÁÙ´²Ç°Ò©Ð§Ñ§¡¢Ò©ÎﶯÁ¦Ñ§¼°Çå¾²ÐÔÆÀ¼ÛÑо¿£¬£¬ £¬£¬£¬ÆäÖÐ3¸öADCÒ©ÎïÑо¿×ÊÁÏÒÑ˳Ëìͨ¹ýNMPAºÍFDAÉóÆÀ£¬£¬ £¬£¬£¬ÁíÍâ1¸ö½«ÔÚ2019ÄêÌá½»NMPAÉóÆÀ¡£¡£¡£
ÀÏÒ©ÐÂÓ÷ΰ©°ÐÏòÒ©ÎォӭÀ´2.1ʱ´ú
2018-02-05
µ½ÏÖÔÚΪֹ£¬£¬ £¬£¬£¬ÔÚ°©Ö¢ÖÎÁƵļ¼ÊõÁìÓòÖÐÒ»¹²·ºÆðÁËÈý´ÎÀúÊ·Éϵı¼ÌÚ£¬£¬ £¬£¬£¬µÚÒ»´Î±¼ÌÚÊÇ´Ó1943Äê×îÏÈ£¬£¬ £¬£¬£¬ÒÔÖÖÖÖϸ°û¶¾»¯ÁÆÒ©ÎïΪÖ÷ÒªÖÎÁÆÊֶεÄ1.0ʱ´ú¡£¡£¡£µÚ¶þ´Î±¼ÌÚÊÇ´Ó1990Äê×îÏÈÑо¿£¬£¬ £¬£¬£¬ÔÚ2000ÄêÒÔºó×îÏÈÔÚÁÙ´²ÉÏʹÓ㬣¬ £¬£¬£¬ÖÁ½ñÒÑ»ñµÃÆÕ±éÓ¦ÓõİÐÏòÒ©Îï¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿